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Background. Plasmodium (P) falciparum malaria is a major life-threatening infectious 
disease associated with systemic inflammation. Heme and its detoxification product hemozoin 
are inflammatory stimuli during the intraerythrocytic phase of the P. falciparum life cycle. 
The aim of this study was to investigate the impact of complement activation and its possible 
relation to cytokine responses in malaria pathology. 
Methods. Blood samples from 131 patients with confirmed P. falciparum malaria, and 
plasma from human whole blood incubated ex vivo with hemin (heme oxidized form) or 
natural hemozoin were analyzed for complement activation, measured as C3bc, C5a, and the 
soluble terminal complement complex C5b-9 (sC5b-9) through ELISA, and for cytokines 
using a multiplex assay. Complement dependency on cytokine release was studied using 
specific inhibitors of C3, C5 and the C5a receptor 1 (C5aR1).  
Findings. sC5b-9 was significantly increased in the malaria cohort as compared to healthy 
controls. The sC5-9 levels positively correlated to disease severity (p<0.05), and with levels 
of certain cytokines, and in particular IL-8/CXCL8 (rs=0.52, p<0.01), that were significantly 
elevated in these patients. Hemin and hemozoin induced substantial complement activation 
and release of cytokines, in particular IL-8/CXCL8, ex vivo. All complement inhibitors 
significantly blocked the IL-8/CXCL8 increase, with similar effects of C3, C5 and C5aR1 
inhibition, showing that these effects are mediated through C5aR1 activation. 
Interpretations. P. falciparum malaria was associated with a systemic complement activation 
correlated with levels of certain inflammatory cytokines in vivo, of which IL-8/CXCL8 was 








This study was financially supported by The Research Council of Norway, The Norwegian 
Council on Cardiovascular Disease, The Western Norway Regional Health Authority, The 
Northern Norway Regional Health Authority, The Southern and Eastern Norway Regional 
Health Authority, The Odd Fellow Foundation, The University of Turin (intramural funding) 








Plasmodium falciparum (P. falciparum) malaria is a major cause of mortality in sub-Saharan 
Africa. About 750,000 to 1.13 million people die globally every year [1, 2]. In light of those 
challenges, together with increasing drug and insecticide resistance, studies of the host’s 
immunological and inflammatory responses during falciparum malaria are important. While a 
balanced immune response could be beneficial for the host, leading to increased clearance of 
the parasite, overwhelming inflammatory responses could lead to tissue damage and 
deleterious effects for the infected patient. The characterization and regulation of this delicate 
balance between beneficial and detrimental immune responses during falciparum malaria is at 
present not clear.  
The complement system is part of the innate immune defense mechanisms against 
microbes and consists of more than 50 membrane-bound and soluble proteins [3, 4]. Recent 
studies suggest that complement can be regarded as a surveillance system that quickly can be 
activated by sensing of danger to the host, by both sterile and non-sterile stimuli, and thereby 
contribute to maintain tissue homeostasis and promote tissue repair [5]. On the other hand, 
undesired or uncontrolled complement activation can induce tissue damage and organ 
dysfunction in the host, as sometimes seen in septicemia and various autoimmune disorders 
[6, 7]. Studies in both humans and animal models have shown extensive complement 
activation during malaria infection [8, 9, 10, 11] though data of terminal complement cascade 
activation, with generation of the terminal complement complex (TCC), are scarce. In 
addition, it is still not clear how malaria parasites induce complement activation and how 





An important stimulus in malaria immunopathology is crystalline hemozoin, which is 
produced as a heme detoxification product after hemoglobin catabolism during the intra-
erythrocytic phase of Plasmodium life cycle and released together with the parasite and 
hemoglobin upon rupture of infected erythrocytes [12, 13]. Ferric heme (hemin) is liberated 
from hemoglobin due to oxidation of the heme-moiety within hemoglobin [14, 15]. Hemozoin 
crystals and monomeric hemin have been proposed as modulators of inflammation in malaria 
pathology and have been shown to induce leukocyte activation with generation of 
inflammatory cytokines [13, 16]. Under certain conditions, the release of several cytokines, in 
particular interleukin (IL)-8/CXCL8, is directly dependent on complement activation [17]. 
However, it remains unclear so far whether hemin and hemozoin directly induce complement 
activation and whether complement activation is crucial in cytokine response following 
hemozoin/hemin release.  
The aim of this study was to elucidate the role of complement activation during P. 
falciparum infection. Plasma complement activation products were measured and analyzed 
for correlation to disease severity and cytokine plasma levels in P. falciparum-infected 
patients admitted to the Central Hospital of Maputo in Mozambique. Furthermore, the 
interaction between malaria and complement was studied ex vivo by incubating hemin and 
hemozoin in non-immune human whole blood using a model designed for investigation of 
crosstalk between complement and the remaining inflammatory network [18]. By employing 
complement inhibitors, we were able to document a causal relation between hemin- and 







Study design and participants 
The study population has previously been described [19]. Briefly, during two malaria seasons, 
from 8th January 2011 to 31st March 2011 and from 7th November 2011 to 14th March 2012 
we collected clinical data and blood samples from all adult nonpregnant patients admitted to 
the Central Hospital of Maputo, Mozambique with an axillary temperature ≥ 38°C and/or 
suspected malaria. Of the 212 screened patients, 131 were found to have P. falciparum 
malaria as assessed by PCR (n=129) or antigen test/slides (n=2). Of the 131 malaria patients, 
70 were found to be HIV-infected as assessed by PCR and/or serological tests [19]. Severe 
malaria and very severe malaria were defined as more than one and three or more malaria 
severity criteria, respectively, modified from the definition of severe malaria by WHO [19, 
20]. For comparison, health care workers and their family and friends were included as 
controls (n=52), provided that they were well-being and had a healthy appearance as 
evaluated by the researcher. All included controls were negative for P. falciparum and HIV 
infection.   
 
Collection of blood samples and preparation of plasma from patients and controls 
Blood samples from patients and healthy controls were collected from a pre-alcohol-cleaned 
peripheral vein into pyrogenic-free tubes with EDTA. The EDTA vacutainer tubes were 
turned gently, placed immediately on melting ice, and centrifuged within 30 minutes at 2000g 
for 20 minutes to obtain platelet-poor plasma. Plasma was aliquoted and stored first at -20°C 
for 24 hours; then at -80oC. The samples were thawed only once and were analyzed for 
complement and cytokines as described below. 
 




Whole blood was obtained from nonimmune healthy adult volunteers who had received no 
medication for at least 10 days. Blood was drawn from an antecubital vein into 4.5 ml sterile 
polypropylene cryotubes (Nalgene NUNC, Roskilde, Denmark) containing the thrombin 
specific inhibitor lepirudin (Refludan; Pharmion ApS, Copenhagen, Denmark) at a final 
concentration of 50 g/ml. Lepirudin was used as anticoagulant in all ex vivo experiments. 
The samples were analyzed for complement and cytokines as described below.  
 
Complement assays 
The complement activation products C3bc and the sC5b-9 were analyzed using enzyme-
linked immunosorbent assays (ELISAs) as described in detail previously [21]. Briefly, the 
assays were based on monoclonal antibodies detecting neo-epitopes exposed after activation 
of the components, thus specifically measuring only the activated component. The amount of 
activation products present is related to an international standard defined to contain 1000 
complement arbitrary units (CAU)/ml. C5a was analyzed in plasma using the commercial 
ELISA DuoSet kit (R&D systems, Minneapolis, MN) according to the manufacturer protocol. 
Detected C5a is expressed as ng/ml. 
 
Cytokine assays 
Plasma samples from whole blood ex vivo cultured (see below) were analyzed using a 27-Plex 
Panel multiplex cytokine assay (Bio-Rad Laboratories Inc., Hercules, CA) as previously 
described [22]. In the present study the following cytokines were analyzed for their 
correlation to plasma sC5b-9: IL-8/CXCL8, monocyte chemotactic protein 1 (MCP-1)/CCL2, 
macrophage inflammatory protein (MIP)-1β/CCL4, and IL-6. 
 




Hemin (ferriprotoporphyrin IX; Sigma-Aldrich, St. Louis, MO), the ferric oxidized form of 
heme, was dissolved in 20 mM NaOH to 10 mg/ml and kept in dark at 4°C until use. 
Hemozoin was prepared from P. falciparum parasites (Palo Alto strain; mycoplasma free), 
which were kept in culture as previously described [23]. After centrifugation at 5000g on a 
discontinuous Percoll-mannitol density gradient, natural hemozoin was collected from the 0–
40 % interphase and washed and centrifuged at 5000g five times with 10 mM KH2PO4 (pH 
8.0) containing 10 mM mannitol at 4°C, and once with PBS. After quantification of heme 
content by luminescence [24], natural hemozoin was stored at 20 % (v/v) in PBS at -20°C. 
 
Complement inhibitors  
For complement inhibition, compstatin (Cp40 analogue (dTyr-Ile-[Cys-Val-Trp(Me)-Gln-
Asp-Trp-Sar-His-Arg-Cys]-mIle-NH2) was used to specifically target C3 [25]. C5 was 
blocked using eculizumab (Alexion Pharmaceuticals, Inc. Cheshire, CT) and the C5a-receptor 
1 (C5aR1, CD88) inhibitor AcF[OPdChaWR], synthesized as previously described [26], was 
used for blockade of the C5aR1. Compstatin and C5aR1 inhibitor were kindly provided by 
prof. John Lambris, University of Pennsylvania.  
 
Ex vivo whole blood activation  
The inflammatory response in whole blood was studied by incubating hemin or hemozoin in 
1.8 ml round-bottom sterile polypropylene NUNC cryotubes (Nalgene NUNC) on rotation for 
4 hours at 37°C. Following incubation, EDTA was added to a final concentration of 20 mM 
and the blood was centrifuged to platelet-poor plasma (3000g for 20 minutes at 4°C) which 
was immediately isolated and stored at -80°C until further analysis. 
 




To characterize the hemin-induced cytokine production in blood and to study the complement 
dependency thereof, hemin 1000 μg/ml and hemozoin 10 μg/ml were incubated in lepuridin-
anticoagulated whole blood supplemented with the complement inhibitors compstatin (20 
M), eculizumab (100 g/ml), and C5aR1 inhibitor (20 M). The inhibitors were pre-
incubated in whole blood for 5 minutes prior to the addition of hemin or hemozoin. 
Incubation was carried out on rotation at 37°C, four hours for complement activation and 
cytokine generation and 15 minutes for expression of CD11b. Following incubation, EDTA 
was added and plasma was isolated as described above. Zymosan A 1000 g/ml (from 
Saccharomyces cerevisiae, Sigma-Aldrich) and ultrapure LPS 100 ng/ml (from E. coli strain 
O111:B4; InvivoGen, San Diego, CA) served as positive controls for complement activation 
and cytokine generation, respectively. 
 
Expression of CD11b 
Expression of CD11b on granulocytes and monocytes was detected using flow cytometry. 
Whole blood was pre-incubated with complement inhibitors as described above and incubated 
with hemin 1000 g/ml for 15 minutes. Cells were then fixed using 0.5 % (v/v) 
paraformaldehyde for 4 minutes at 37°C, before staining with anti-CD11b-PE (D12, BD 
Biosciences), anti-CD14-FITC (MφP9, BD Biosciences) and anti-CD45-PerCP (2D1, BD 
Biosciences) for 15 minutes at room temperature. Red blood cells were then lysed and the 
samples washed and assayed on a FACSCalibur flow cytometer (BD Biosciences). 
Leukocytes were gated as CD45+ cells, and granulocytes and monocytes were separated based 
on their CD14 expression. Data were collected using Cell Quest Pro (v 5.2.1, BD 






Differences between the patient groups were tested by chi square test for categorical variables 
and with Mann-Whitney test for continuous data. Correlations between sC5b-9 and cytokines 
were investigated using Spearman’s Rank Order Correlation. Results from the ex vivo 
experiments are presented in scattered plots as means and 95 % confidence intervals. For 
statistical analysis, the values from hemin and hemozoin were compared to those of buffer 
controls and significance was calculated using paired t-test. If significantly separated (p< 
0.05), hemin and hemozoin were further compared to hemin and hemozoin supplemented 
with complement inhibitors using one-way ANOVA followed by Dunnett´s multiple 
comparisons test using GraphPad Prism version 6.0d for MAC OS X (GraphPad Software, La 
Jolla CA). When pairing was significantly effective (p<0.05), statistical significance was 
calculated using repeated measurements ANOVA with Dunnett´s post-hoc test and corrected 
for unequal sphericity (Geisser-Greenhouse correction). 
 
Role of the funding source 
The sponsors had no role in study design, data collection, data analysis, data interpretation, or 
writing the report. The corresponding author had full access to all data in the study and the 
final responsibility for the decision to submit for publication. 
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Demographic patient data 
The patient population has previously been described [19]. Briefly, a total of 212 non-
pregnant adults with fever and/or suspected malaria were screened and 131 had P. falciparum 
malaria, and of these, 70 were co-infected with HIV, and two were co-infected with P. vivax 
and P. malariae, respectively. In addition, 52 healthy controls were included (see Methods). 
 
In vivo complement activation during P. falciparum infection 
Patients with P. falciparum malaria had markedly raised plasma levels of sC5b-9 as compared 
with healthy controls with increasing levels according to disease severity (Figure 1). In fact, 
patients with the most severe malaria had significantly raised levels of sC5b-9 not only as 
compared with healthy controls (p<0.001), but also as compared with malaria patients with 
less severe disease (p<0.05) (Figure 1). Seventy of the patients were co-infected with HIV-1, 
and we have previously shown that these patients were characterized by more severe malaria 
disease [19]. HIV-co-infected patients had moderately higher sC5b-9 levels than the other 
malaria patients (2.0 CAU/mL versus 1.4 CAU/mL, data are given as medians and 25th-75th 
percentiles, p<0.01).  
 
Correlation between complement activation and cytokines 
We have previously published data on cytokine levels in these malaria patients [22]. Plasma 
levels of sC5b-9 significantly correlated to the levels of four of the cytokines that were raised 
in malaria patients as compared with controls: IL-6 (rs=0.63), IL-8/CXCL8 (rs=0.52), MCP-




receptor antagonist, IL-9, IL-10, eotaxin/CCL11, interferon inducing protein-10 (IP-
10)/CXCL10 were also increased in the patients [22], but did not correlate with sC5b-9. 
 
Hemin-induced inflammatory response in human whole blood ex vivo 
Complement activation  
Hemin is released from erythrocytes during malaria infection and is thought to contribute to 
the inflammatory response during parasitemia [14]. To further elucidate the interaction 
between malaria and complement, we examined the ability of hemin to induce complement 
activation in whole blood from healthy controls. Incubation of hemin caused a dose-
dependent complement activation detected as generation of sC5b-9 (Figure 3A). Hemin at 
1000 g/ml was significantly increased over the buffer control and was used in the following 
experiments. Hemin caused a strong complement activation detected as C3bc, C5a, and sC5b-
9 formation (Figure 3B-D). Complement inhibitors blocking the cleavage of C3 (compstatin) 
completely prevented generation of all three activation products whereas blocking of C5 
(eculizumab) completely prevented generation of C5a and sC5b-9 (Figure 3). As expected, 
none of the activation fragments were affected by the C5aR1 inhibitor (Figure 3).  
 
Effect of complement inhibition on hemin-induced cytokine release 
We have previously reported that these malaria patients are characterized by increased plasma 
levels of several cytokines as compared with healthy controls [22], and as described above, 
plasma levels of IL-6, IL-8/CXCL8, MCP-1/CCL2 and MIP-1/CCL4 were significantly 
correlated with plasma levels of sC5b-9 (Figure 2). Interestingly, hemin induced a robust 
release of IL-6, IL-8/CXCL8 and MCP-1/CCL2, but not MIP-1/CCL4, in whole blood after 




and the complement dependency thereof was then examined by the use of complement 
inhibitors as described above. The levels of all three were all significantly lower in the 
presence of all tested complement inhibitors, including C5aR1 inhibition (p<0.01) (Figure 4). 
No significant differences were observed between the respective inhibitors, implying 
downstream C5aR1 inhibition as effective as upstream C3 inhibition. We have previously 
showed a particularly strong association of IL-8/CXCL8 and disease severity in these malaria 
patients and it is noteworthy that the hemin-induced IL-8/CXCL8 response was particularly 
prominent (13-fold increase over basal) and this response was substantially counteracted by 
complement inhibition (Figure 4). 
 
Effect of complement inhibition on hemin-induced CD11b expression 
Up-regulation of adhesion molecules on leukocytes like CD11b is of importance for vascular 
inflammation during malaria infection. Therefore, the ability of hemin to induce CD11 
expression on leukoytes in whole blood was tested. Early hemin-induced leukocyte activation 
was detected as significant (p<0.001) up-regulation of CD11b on granulocytes (Figure 5). The 
increase was substantially inhibited in the presence of complement inhibitors. Hemin also 
induced CD11b expression on monocytes but the effect of complement inhibitors was in the 
monocyte population quantitatively marginal. 
 
Hemozoin induces complement activation ex vivo in whole blood 
As mentioned, the malaria parasite produces crystalline hemozoin upon the breakdown of 
hemoglobin. To examine whether hemozoin behaved similar to hemin with respect to 
complement activation and IL-8/CXCL8 release, whole blood was incubated with P. 
falciparum-hemozoin. This caused a significant (p<0.01) complement activation detected as 




similarly to previous observations with hemin, the IL-8/CXCL8 response was significantly 
(p<0.05) increased upon exposure of hemozoin, and the effect was substantially inhibited by 






We demonstrate here that patients with P. falciparum malaria have increased complement 
activation systemically as compared to healthy controls, as shown by increased levels of 
sC5b-9, demonstrating that the complement cascade is activated to the very end during 
falciparum malaria. In particular, high sC5b-9 levels were found in patients with a more 
severe form of the disease as compared to a milder variant, and correlated with levels of 
certain inflammatory cytokines (i.e., IL-6, IL-8/CXCL8, MCP-1/CCL2 and MIP-1CCL4) 
that also were elevated in these patients. Furthermore, we document a causal association 
between complement activation and three of these cytokines in ex vivo experiments, where 
hemin and hemozoin-induced cytokine release, and in particular IL-8/CXCL8, was found to 
be complement-mediated.    
Increased levels of sC5b-9 in malaria patients correlating to disease severity are in line 
with some previous reports. A small cohort (n=15) of healthy volunteers experimentally 
infected with the P. falciparum had increased levels of sC5b-9 in the early stage of the 
infection [10]. In another study, 23 patients with severe falciparum malaria had increased 
levels of sC5b-9 together with the complement activation fragment Bb [11]. C5a elevation has 
been reported in children with cerebral malaria [27] and in primigravid women with placental 
malaria [28]. Evidence on complement components consumption as a result of malaria 
paroxysm is also reported in some older studies [29-31].  
In the present study we extend these previous findings by examining a relatively large 
population of adult patients with P. falciparum infection, showing a marked increase in sC5b-
9 in these patients with particularly high levels in those with the most severe disease, 
significantly correlated with plasma levels of IL-6, IL-8/CXCL8, MCP-1/CCL2 and MIP-




response in pro-inflammatory cytokines in an inflammatory disease as malaria, and we cannot 
exclusively state that the cytokines elevated here are a result of complement activation. 
Nevertheless, it is interesting that these particular mediators correlated to sC5b-9. Since 
complement is a pattern recognition system and early activated during infection, it is tempting 
to speculate that complement activation is among the factors triggering cytokine release. 
Induction of IL-8/CXCL8 and MCP-1/CCL2 regularly follows complement activation 
induced by a number of stimuli and is reduced in complement-deficient blood or in the 
presence of complement inhibitors [17, 32-37]. Sublytic levels of membrane C5b-9 can also 
induce direct secretion of the IL-8/CXCL8 and MCP-1/CCL2 chemokines from endothelial 
cells [38, 39]. This finding could be relevant for the situation in severe falciparum malaria. 
Our findings in the ex vivo part of the study may further support a link between 
complement activation and induction of certain inflammatory cytokines during falciparum 
malaria. We show that hemin and hemozoin, which are released upon erythrocyte rupture, are 
both potent complement activators in human whole blood and that this activation 
subsequently leads to the generation of pro-inflammatory molecules, mediated by the 
interaction of C5a to the C5aR1 as targeted inhibition of C3 and C5 activation were equally 
efficient to that of C5aR1 inhibition. Rupture of parasitized erythrocytes exposes the innate 
immune system to a variety of potential activating agents, which besides hemin and hemozoin 
include plasmodium DNA and glycosylphosphatidylinositol anchors, which can contribute to 
the innate immune response [40, 41]. Hemin and hemozoin are released in large quantities 
[42] have respectively been proposed as modulators of inflammation in malaria [12, 13], and 
as for hemin, also in hemolytic diseases in general [16, 43]. Here, they were hypothesized 
them to be potential agents responsible for triggering complement activation during 
falciparum malaria. The form of hemozoin tested was the natural variant produced by the P. 




natural and synthetic hemozoin, which might be attributed to further lipids, DNA and proteins 
bound to natural hemozoin [12]. Since the aim of the present work was to use the most 
physiologically relevant form of malaria pigment, natural hemozoin was employed without 
being delipidized or freed from proteins and DNA.  
Hemin, which represents the Fe3+-oxidized form of heme, is liberated extracellular 
from the hemoglobin released upon erythrocyte rupture and is derived via reactive oxygen 
species [44]. We found hemin to activate complement in whole blood culture in a dose-
dependent manner, and a concentration of 1000 g/ml was chosen for further experiments. 
Hemin is efficiently scavenged by hemopexin in plasma [45], and concentrations of 100 
g/ml hardly cause activation above background levels. Hemin has previously been shown to 
modulate complement activation. Frimat et al. demonstrated that hemin was a potent activator 
of the alternative pathway [46], simultaneously inhibiting classical complement activation, as 
shown previously [47]. We found both hemozoin and hemin to be able to activate 
complement, hemozoin already at 10 g/ml, a concentration at which hemin did not generate 
any sC5b-9. Nonetheless, both hemin and hemozoin potently induced IL-8/CXCL8 release, 
the cytokine most strongly associated with disease severity in patients, and this response was 
markedly abolished by complement inhibition, further supporting a link between complement 
activation and IL-8/CXCL8 release in falciparum malaria. 
Hemin-induced granulocyte activation was substantially complement-dependent, 
whereas the corresponding monocyte activation was not. This is consistent with a previous 
report showing hemin-induced activation of neutrophils and a subsequent release of IL-
8/CXCL8 [16]. Thus, whereas the effect on granulocytes was apparent, it is hard to draw any 
conclusions on which physiological consequences complement inhibition has on the hemin-




Interaction of C5a with the C5aR1 seems to be the central mechanism for the 
induction of the cytokines that we found up-regulated ex vivo. C5a is a main contributor of 
complement-mediated inflammatory response, implicated in various clinical frames, e.g. 
sepsis [48], sharing similarities with the inflammatory response in malaria [49, 50]. The 
impact of C5 in malaria is highlighted in studies of experimental malaria in mice. C5 deficient 
mice are shown to be resistant to infection with P. berghei ANKA as compared to C5 
sufficient mice, and they do not develop experimental cerebral malaria [51, 52]. Both C5a 
interaction with C5aR1 [27, 51] and membrane incorporation of C5b-9 [52] have been 
described as harmful C5-dependent mechanisms in murine experimental malaria. C5a is also 
proposed as a mediator for cytokine release in placental malaria [28] and seems to play a key 
role for the effects observed in the present study. In addition to induction of certain cytokines, 
the hemin-induced up-regulation of CD11b on granulocytes seemed to be dependent on 
C5aR1 activation. IL-8/CXCL8 is a potent chemoattractant and activator of granulocytes, and 
the combined C5aR1-dependent activation of IL-8/CXCL8 and the adhesion molecule CD11b 
in granulocytes in hemin-exposed whole blood, may suggest an important role for 






We postulate complement activation to be an important component in malaria 
pathophysiology, contributing to triggering a systemic inflammatory response and 
exacerbation of the disease. We show that hemozoin and hemin are potent complement 
activators in whole blood and that the resulting inflammatory response is largely dependent on 
interaction of C5a with the C5aR1. Translation of ex vivo findings to the in vivo situation 
should be made with caution. Still, our findings underscore C5a as a potential contributor to 
the malaria pathogenesis, and the C5a interaction with C5aR1 as a potential target for the 
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Figure 1. Complement activation as measured by sC5b-9 and relation to malaria severity score. 
Plasma samples from patients with P. falciparum malaria were analyzed for the complement activation 
product sC5b-9. Patients were divided into two groups based on Malaria Severity Score (MSS) <3 
(n=114) or ≥3 (n=15), and related to healthy controls (HC) (n=52). Levels of sC5b-9 are presented in 
the figure as box-and-whiskers plot with 5-95 percentile range, *=p<0.05, ***p<0.001.    
 
Figure 2: Correlation of sC5b-9 to IL-6, IL-8/CXCL8, MCP-1/CCL2 and MIP-1β/CCL4 in the 
malaria patients. Correlation of sC5b-9 to cytokines in plasma samples of malaria patients (n=131) 
was tested using Spearman’s Rank Order Correlation on logarithmic values. Significant (p<0.01) 
positive correlation was found between sC5b-9 and each of the following variables, with rs=0.63 for 
IL-6 (A), rs=0.52 for IL-8/CXCL8 (B), rs=0.62 for MCP-1/CCL2 (C) and rs=0.62 for MIP-1β/CCL4 
(D) respectively. Linear values are plotted in graphs on logarithmic scale.  
 
Figure 3. Complement activation by hemin in whole blood ex vivo.  
Hemin was incubated for four hours in whole blood. Dose-dependent complement response to hemin 
was tested with hemin 10-1000 g/mL; complement activation was detected as sC5b-9 (A). Hemin 
(1000 g) was then incubated in the presence or absence of complement inhibitors at the level of C3 
(compstatin), C5 (eculizumab), and C5aR1 (C5aRag). Complement activation was detected as 
generation of C3bc (B), C5a (C) and sC5b-9 (D). Zymosan (1000 μg/ml) served as positive control. 
Data are presented as means and 95 % confidence intervals; n=6; *p<0.05, ***p<0.001, ns=non-
significant.   
 
Dose-dependent complement response to hemin was investigated by incubating hemin 10-1000 g/mL 





Figure 4. Cytokine release ex vivo in whole blood incubated with hemin with or without 
complement inhibitors. 
Hemin-induced increase in IL-6 (A), IL-8/CXCL8 (B) and MCP-1/CCL2 (C) in comparison to the 
buffer control is depicted. Complement inhibition at all tested levels (C3, C5, C5aR1) are shown. Data 
are presented as means and 95 % confidence intervals; n=6; *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 5. Effect of hemin on up-regulation of CD11b on granulocytes in whole blood. 
Up-regulation of CD11b on granulocytes and monocytes was examined after 15 minutes whole blood 
incubation of hemin with or without complement inhibitors. Expression of CD11b specifically 
analyzed in the granulocyte population measured as Mean Fluorescence Intensity (MFI) is shown in 
the figure. Complement inhibitors are as described in Figure 3. Data are presented as means and 95 % 
confidence intervals; n=6; **p<0.01, ***p<0.001. 
 
Figure 6.  Effect of hemozoin on complement activation ex vivo in a whole blood model. 
Hemozoin was incubated for four hours in the presence or absence of complement inhibitors at the 
level of C3 (compstatin), C5 (eculizumab), and C5aR1 (C5aRA). The degree of complement 
activation was investigated as sC5b-9 (A) and the effect of complement inhibitors on the IL-8/CXCL8 
release was investigated (B). Data are presented as means and 95 % confidence intervals; n=5 
(C5aRA, n=4; LPS, n=3); *p<0.05, **p<0.01, ns=non-significant. 
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